Literature DB >> 22116937

Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.

A Giralt1, M Puigdellívol, O Carretón, P Paoletti, J Valero, A Parra-Damas, C A Saura, J Alberch, S Ginés.   

Abstract

Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder caused by an expanded CAG/polyglutamine repeat in the coding region of the huntingtin (htt) gene. Although HD is classically considered a motor disorder, there is now considerable evidence that early cognitive deficits appear in patients before the onset of motor disturbances. Here we demonstrate early impairment of long-term spatial and recognition memory in heterozygous HD knock-in mutant mice (Hdh(Q7/Q111)), a genetically accurate HD mouse model. Cognitive deficits are associated with reduced hippocampal expression of CREB-binding protein (CBP) and diminished levels of histone H3 acetylation. In agreement with reduced CBP, the expression of CREB/CBP target genes related to memory, such c-fos, Arc and Nr4a2, was significantly reduced in the hippocampus of Hdh(Q7/Q111) mice compared with wild-type mice. Finally, and consistent with a role of CBP in cognitive impairment in Hdh(Q7/Q111) mice, administration of the histone deacetylase inhibitor trichostatin A rescues recognition memory deficits and transcription of selective CREB/CBP target genes in Hdh(Q7/Q111) mice. These findings demonstrate an important role for CBP in cognitive dysfunction in HD and suggest the use of histone deacetylase inhibitors as a novel therapeutic strategy for the treatment of memory deficits in this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116937     DOI: 10.1093/hmg/ddr552

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  53 in total

Review 1.  The role of histone acetylation in memory formation and cognitive impairments.

Authors:  Lucia Peixoto; Ted Abel
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

3.  High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds.

Authors:  Seth A Ament; Jocelynn R Pearl; Andrea Grindeland; Jason St Claire; John C Earls; Marina Kovalenko; Tammy Gillis; Jayalakshmi Mysore; James F Gusella; Jong-Min Lee; Seung Kwak; David Howland; Min Young Lee; David Baxter; Kelsey Scherler; Kai Wang; Donald Geman; Jeffrey B Carroll; Marcy E MacDonald; George Carlson; Vanessa C Wheeler; Nathan D Price; Leroy E Hood
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

4.  The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease.

Authors:  Juliana G Doria; Jessica M de Souza; Flavia R Silva; Isabella G Olmo; Toniana G Carvalho; Juliana Alves-Silva; Talita H Ferreira-Vieira; Jessica T Santos; Claudymara Q S Xavier; Nathalia C Silva; Esther M A Maciel; Peter Jeffrey Conn; Fabiola M Ribeiro
Journal:  J Neurochem       Date:  2018-09-11       Impact factor: 5.372

5.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

6.  Onset of Huntington's disease: can it be purely cognitive?

Authors:  Jane S Paulsen; Jeffrey D Long
Journal:  Mov Disord       Date:  2014-08-20       Impact factor: 10.338

Review 7.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

8.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

9.  Inositol polyphosphate multikinase is a transcriptional coactivator required for immediate early gene induction.

Authors:  Risheng Xu; Bindu D Paul; Dani R Smith; Richa Tyagi; Feng Rao; A Basit Khan; Daniel J Blech; M Scott Vandiver; Maged M Harraz; Prasun Guha; Ishrat Ahmed; Nilkantha Sen; Michela Gallagher; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.